A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: iStock
A parliamentary committee in Canada has recommended that the country's assisted dying laws continue to exclude people whose sole underlying condition is a mental illness.
According to the committee's report, Canada's assisted dying framework should "indefinitely exclude" individuals whose only medical condition is a mental illness.
Canada first passed its assisted dying legislation, known as Bill C-14, in 2016, marking a significant development in healthcare and personal autonomy.
Officially known as Medical Assistance in Dying (MAID), the law initially applied only to adults who were terminally ill. However, eligibility for MAID has remained one of the country's most contentious healthcare issues over the past decade, with plans to expand access delayed twice.
The 98-page report by the joint House and Senate committee on Medical Assistance in Dying contains a single recommendation: that Canada "indefinitely exclude persons whose sole underlying medical condition is a mental illness from eligibility for medical assistance in dying", according to the BBC.
The report noted a "divergence of perspectives" on the issue and highlighted concerns raised during testimony about the "pressing need for increased and more equitable access to adequate mental health services".
However, some committee members disagreed with the findings and published a dissenting report, arguing that the process was "fundamentally flawed", "biased", and favored testimony from those opposed to expanding MAID. Canada's government must respond to the report by July 11.
Also read: Noelia Castillo: 25-year-old Spanish Woman Dies By Euthanasia After Long Legal Battle
When MAID was introduced in 2016, it was available only to adults who were terminally ill.
The eligibility criteria were strict. Individuals had to be suffering from a "serious and incurable illness", be in an "advanced state of irreversible decline", experience "intolerable suffering", and have a natural death that was "reasonably foreseeable".
This legal pathway became known as Track 1. Modelled on end-of-life care, it primarily served people with terminal cancer or other severe illnesses who wanted greater control over the dying process. Track 1 remains a relatively swift procedure, with some patients receiving MAID within a day of applying.
Read More: Passive Euthanasia: Harish Rana’s Case May Reshape End-of-life Protocols, Say Experts
However, many Canadians living with severe non-terminal conditions argued that they were excluded from the law. These included people with degenerative diseases, chronic pain, or spinal injuries who experienced significant suffering but were not nearing death. Many requested MAID but were routinely denied.
In 2019, the country introduced Bill C-7 in 2021, creating Track 2 and extending MAID eligibility to people with serious, incurable conditions causing enduring suffering even when death was not foreseeable.
Track 2 includes additional safeguards, including a 90-day assessment period, evaluation by two independent clinicians, and consultation with specialists when necessary.
Despite its stricter safeguards and ethical complexities, Track 2 MAID has steadily gained use. In 2023, there were 622 deaths under Track 2 compared with 14,721 under Track 1.
Supporters view Track 2 as a compassionate option for people living with severe, non-terminal suffering, while critics argue it risks exposing vulnerable populations to premature death.
In 2023, Canada first delayed eligibility for MAID for people whose sole condition was a mental illness by one year, citing concerns that the healthcare system was not ready for the expansion. The government later delayed implementation again until March 17, 2027.
Along with the second delay, the government recommended that a parliamentary committee undertake a comprehensive review of the proposal.
According to the latest available figures from 2024, MAID accounts for around 5 per cent of all deaths in Canada. About 96 per cent of MAID cases involved people whose deaths were reasonably foreseeable, most of them terminal cancer patients.
The remaining 4 per cent involved patients whose deaths were not imminent but who had a "grievous and irremediable medical condition".
Credit: iStock
The United States is witnessing a rise in cases of Powassan virus disease, a rare but potentially deadly illness transmitted through tick bites. Unlike many other tick-borne diseases, Powassan virus can be transmitted within 15 minutes of a tick attaching to the skin, making prevention and awareness especially important.
According to the US Centers for Disease Control and Prevention (CDC), tick exposure can occur throughout the year, although ticks are most active during the warmer months between April and September.
Emergency physician Dr. Rick Pescatore recently highlighted the growing threat in a TikTok video post, warning that many people remain unaware of the virus despite its severe health consequences.
"There's a new and deadly tick virus that's spreading across the United States, and you probably haven't heard about it," he said.
Pescatore emphasized the seriousness of the infection, noting that "about one in 10 people with severe disease die, while around half of survivors may experience permanent neurological damage". He also claimed that reported cases have increased steadily over the past decade.
Several state health departments have urged residents to take precautions after reporting cases of the rare disease.
In one recent case, a 66-year-old man from New Hampshire was hospitalized for several weeks after contracting the virus. After initially being admitted to Concord Hospital, he was later transferred to Massachusetts General Hospital for specialized care.
Also read: Taking Duloxetine? US FDA Warns of Cancer-Causing Impurity in Antidepressant
The Powassan virus is named after the town of Powassan in Ontario, Canada, where it was first identified in 1958. It belongs to the flavivirus family, which also includes viruses that cause Zika, dengue, and West Nile fever.
The virus is primarily spread by the black-legged tick (Ixodes scapularis), also known as the deer tick, which is also responsible for transmitting Lyme disease.
However, unlike Lyme disease—which generally requires a tick to remain attached for more than 24 hours before transmission—Powassan virus can be transmitted in as little as 15 minutes, according to the Massachusetts Department of Public Health.
Read More: South Korea Achieves 62% Blood Pressure Control Rate: What Other Countries Can Learn
Symptoms typically develop between seven and 30 days after a tick bite and may include:
These complications can lead to long-term neurological damage. According to Yale Medicine, approximately 10 per cent of severe cases are fatal, while nearly 50 per cent of survivors experience lasting neurological problems.
One of the most concerning aspects of the Powassan virus is that there is currently no vaccine or antiviral treatment available.
Unlike Lyme disease, which can be treated with antibiotics, Powassan virus has no specific cure. Medical care focuses on managing symptoms and supporting patients with severe disease.
As a result, prevention remains the most effective defense against infection.
The CDC and the National Institutes of Health (NIH) recommend the following measures to reduce the risk of tick bites:
If you find a tick attached to your skin, remove it promptly using fine-tipped tweezers.
Credit: WHO
Amid the ongoing Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC), the World Health Organization (WHO) has released its first comprehensive guidelines for the clinical management of filovirus diseases, a group that includes all Ebola and Marburg virus infections.
Ebola and Marburg diseases are severe, often fatal illnesses that have caused repeated outbreaks across Africa. Since the discovery of the Marburg virus in 1967, there have been 72 documented outbreaks of Ebola and Marburg diseases.
There are currently no licensed vaccines and treatments for Marburg virus disease, as well as Bundibugyo and Sudan virus diseases. Thus, the WHO emphasized that early supportive care remains one of the most effective ways to improve survival.
"The current Bundibugyo virus outbreak is a stark reminder of the need for diligent, holistic and person-focused medical care to save lives and preserve human dignity. We encourage governments and authorities to integrate these new recommendations into preparedness and outbreak response to ensure high-quality care for everyone," said WHO Director-General Dr. Tedros Adhanom Ghebreyesus.
Also read: Ebola Bundibugyo Outbreak: UK Scientists Identify 23 Unique Mutations
The WHO has previously published disease-specific guidance on Ebola care and therapeutics. However, the newly released guidelines are the first to provide a comprehensive framework covering all filovirus diseases, including Ebola and Marburg.
Developed through consultations with global experts and based on the latest scientific evidence, the guidelines contain 16 evidence-based recommendations focused on improving supportive care and reducing mortality.
The recommendations are designed to help frontline healthcare workers:
Key Recommendations include:
The WHO also recommended structured after-care programs for survivors to support recovery, improve long-term well-being, and reduce the risk of infections linked to viral persistence after recovery.
For Bundibugyo virus disease and other filovirus infections, WHO stressed that early recognition, rapid referral, and optimized supportive care remain the foundation of patient management.
Effective supportive care can reduce complications, improve survival, and provide the basis for evaluating potential antiviral treatments through future clinical research.
Meanwhile, the Africa Centers for Disease Control and Prevention (Africa CDC) has raised concerns about significant weaknesses in contact-tracing efforts during the ongoing outbreak.
According to Africa CDC Director-General Dr. Jean Kaseya, more than 28,000 people who have been in contact with confirmed Ebola patients are currently not being monitored.
Responders should be tracking approximately 33,080 contacts, but only 4,112 are being actively followed, he said during a high-level meeting.
The agency warned that the outbreak is spreading at a pace that surveillance systems are struggling to keep up with.
Read More: Ebola Survivors May Face COVID-Like Memory Loss and Brain Issues For Over 7 Years: NIH Study
As per latest update till June 15, there are 827 confirmed Ebola cases linked to the outbreak in the Congo and 196 confirmed death.
Health officials estimate that each infected person may have come into contact with around 40 other individuals, creating a large pool of people at risk of infection.
Because Ebola can take up to 21 days for symptoms to appear, all identified contacts should ideally be monitored throughout the incubation period.
Africa CDC officials cautioned that without stronger surveillance and contact-tracing efforts, controlling the outbreak will become increasingly difficult, despite advances in clinical care and patient management.
© 2024 Bennett, Coleman & Company Limited